Filing scope and business context
The supplied filing is Check-Cap Ltd.’s audited Form 20-F for the fiscal year ended December 31, 2019, filed March 6, 2020—not a quarterly filing and not a filing identified as Mbody AI Ltd. The company is an Israeli clinical-stage medical diagnostics developer listed on Nasdaq as CHEK. It is developing C-Scan, an ingestible, ultra-low-dose X-ray capsule system intended to screen for colorectal polyps without bowel preparation. The financial statements are prepared under U.S. GAAP.
Financial results and position
Amounts below are in U.S. dollars; financial statement amounts are rounded to millions where indicated. Check-Cap had no revenue from inception through 2019, so revenue-based margins are not meaningful.
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | None | None | No product sales to date |
| Research and development, net | $10.47 million | $7.62 million | Up 37.4% |
| General and administrative | $3.60 million | $3.45 million | Up 4.4% |
| Operating loss | $14.07 million | $11.06 million | Loss widened about 27% |
| Net loss | $13.84 million | $10.59 million | Loss widened $3.25 million |
| Basic and diluted loss per share | $1.73 | $2.61 | Improved per share, with higher weighted-average shares |
| Net cash used in operating activities | $12.84 million | $10.11 million | Cash burn increased |
At December 31, 2019, cash and cash equivalents were $7.69 million, restricted cash was $0.35 million, and working capital was $5.63 million, down from $12.76 million a year earlier. Total assets were $9.43 million and shareholders’ equity was $6.23 million. The filing does not report material borrowings; it reports lease liabilities of $0.43 million and royalty-related provisions of $0.18 million. No profitability or operating margin is reported because there was no revenue.
Cash used in investing activities was $5.45 million provided in 2019, mainly reflecting release of short-term deposits; cash used in investing was $5.72 million in 2018, primarily reflecting investment in deposits. Financing provided $6.51 million in 2019, chiefly from the February 2019 registered direct offering, versus $17.76 million in 2018. Cash, cash equivalents and restricted cash together declined by $0.89 million during 2019 to $8.04 million.
Material changes and operating developments
- Net R&D expense rose by $2.86 million, mainly due to higher salaries, materials, subcontractor and consultant costs, and clinical-trial activity. Grants from the Israel Innovation Authority (IIA) offset $0.09 million in 2019, versus $0.21 million in 2018.
- The 2019 net loss increased despite a lower loss per share; weighted-average shares rose to approximately 7.99 million from 4.06 million, largely reflecting equity issuance. Year-end shares outstanding were 8,272,908.
- Cash declined from $8.57 million at year-end 2018 to $7.69 million at year-end 2019, while working capital fell substantially. A $5.64 million short-term bank deposit held at the end of 2018 was no longer reported at year-end 2019.
- In February 2020, the company closed a private placement of 2,720,178 shares at $1.75 per share, generating approximately $4.76 million gross proceeds. This was a subsequent event, not included in 2019 year-end cash.
Outlook, risks, contingencies, and unusual items
- Funding and going concern: The auditor included a going-concern explanatory paragraph, and management stated that substantial doubt exists about the company’s ability to continue as a going concern. Including the February 2020 placement, management expected cash to fund operations only into July 2020. Further financing is needed; absent timely funding, management said it may cut expenses, scale back trials, license or sell assets, seek an acquisition, cease operations, or pursue bankruptcy protection.
- Development plans: Management planned further development and regulatory work in 2020 and a U.S. pivotal study in late 2020, contingent on regulatory approvals and available capital. It anticipated filing a direct FDA de novo petition in 2021 after a successful pivotal trial. These are plans, not assured milestones. Pilot sales were targeted for Israel in late 2020 and Europe in 2021; the company did not provide a specific launch date or forecast revenue and did not expect significant revenue in the foreseeable future.
- Regulatory and clinical uncertainty: C-Scan had CE Mark approval for the EU, valid to January 1, 2023, and Israeli AMAR approval valid to March 31, 2022, but had no U.S. marketing clearance or approval. The U.S. pivotal study remained subject to FDA input/approval, sufficient clinical evidence, and funding; the FDA could require a more demanding PMA pathway.
- Clinical evidence and device reliability: The 2019 post-CE study reported C-Scan sensitivity of 76% for polyps at least 10 mm and specificity of 82%; FIT sensitivity and specificity were 29% and 96%, respectively. The U.S. pilot reported no device- or procedure-related serious adverse events, but only 28 patients were evaluable and the study was not powered for statistical significance. The company also disclosed technical failures in the current capsule version and an ongoing reliability-improvement plan.
- Concentration and execution risks: The business depends on one product, has no commercial sales experience, and needs to scale manufacturing and establish distribution, reimbursement, and market acceptance. It relies on single-source suppliers for several critical components; the X-ray-source supplier agreement was due to expire December 31, 2020. Manufacturing transfers and transfers of IIA-funded know-how are subject to Israeli restrictions.
- Contingent obligations: The company reported approximately $5.7 million of contingent IIA royalty obligations and approximately $0.18 million due under the BIRD Foundation arrangement, payable under specified conditions. It had paid no royalties to either as of year-end. The IIA obligation may increase under certain manufacturing or technology-transfer circumstances.
- Other exposures: Risks include radioactive-material regulation and disposal, reimbursement uncertainty, product liability, intellectual-property claims, foreign-exchange exposure, and operational concentration in Israel. The filing reported no material litigation and no material off-balance-sheet arrangements. The company believed it was a PFIC for 2019 and could be one in 2020, creating potential U.S. tax consequences for investors.
Most important facts for investors to verify
- Confirm the issuer and period: the supplied document is Check-Cap Ltd.’s FY 2019 Form 20-F, not an Mbody AI Ltd. filing or a standalone 2019 Q4 report.
- Verify post-February 2020 cash, subsequent financing, and the actual runway; the filing’s July 2020 runway estimate was management’s forecast, not a guarantee.
- Track funding needs and dilution, including outstanding warrants and any later equity or debt financing.
- Check whether the FDA accepted the proposed pivotal-trial design, whether the study began and was funded, and whether the expected de novo pathway remained viable.
- Assess whether capsule technical reliability and clinical performance are reproducible in larger, representative populations, including the U.S. pivotal study.
- Confirm commercial readiness: local EU approvals, manufacturing capacity and supplier continuity, reimbursement, distribution partners, and IIA-related restrictions or royalties.